• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CDTX

CDTX

Cidara Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD221.38

+0.00 (+0.00%)

Company Profile

CEO

Jeffrey L. Stein

IPO Date

2015-04-15

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$221.38

Prev. Close

$221.38

Day Low

$221.38

Day High

$221.38

52W Low

$15.22

52W High

$221.42

Market Cap

$5.61B

Volume

2.69M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

12.2%

Avg Negative

4.2%

Avg Neutral

83.6%

News Feed

Cidara Therapeutics (CDTX) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research·8/12/2021·↑ positive

Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results

GlobeNewsWire·8/12/2021·↑ positive

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks Investment Research·8/5/2021·↑ positive

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress

GlobeNewsWire·7/27/2021·↑ positive

Cidara Therapeutics: Rezafungin Data Could Bring Value

Seeking Alpha·7/20/2021·↑ positive

Cidara Therapeutics Provides Leadership Update

GlobeNewsWire·7/1/2021·↓ negative

Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference

GlobeNewsWire·6/14/2021·↑ positive

Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/13/2021·↑ positive

Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results

GlobeNewsWire·5/13/2021·↑ positive

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks Investment Research·5/5/2021·↑ positive